Financial Architects (New Jersey)’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Financial Architects (New Jersey)’s Portfolio ICPT Stock Details ICPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-300	Closed	-$18.1K	–	1632
2017 Q4	$18K	Hold	300	–	–	﹤0.01%	999
2017 Q3	$17K	Hold	300	–	–	﹤0.01%	1004
2017 Q2	$36K	Hold	300	–	–	0.01%	788
2017 Q1	$34K	Hold	300	–	–	0.01%	783
2016 Q4	$33K	Hold	300	–	–	0.01%	702
2016 Q3	$49K	Hold	300	–	–	0.01%	576
2016 Q2	$43K	Buy	+300	New	+$43.7K	0.01%	570

Other funds holding ICPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Financial Architects (New Jersey)'s ICPT Position: Q1 2018 in Review

Financial Architects (New Jersey) sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q1 2018, closing a stake of 300 shares — an estimated $18.1K sold.

Financial Architects (New Jersey) first reported a position in ICPT in Q2 2016 and held it in 7 quarters. The position peaked at $49K in Q3 2016. 147 funds tracked by Wall St. Rank hold ICPT as of Q1 2018.

Financial Architects (New Jersey) reported no remaining Intercept Pharmaceuticals, Inc. position as of Q1 2018 after selling out during the quarter.
Financial Architects (New Jersey) sold 300 Intercept Pharmaceuticals, Inc. shares in Q1 2018, an estimated $18.1K.
Financial Architects (New Jersey) first reported a position in Intercept Pharmaceuticals, Inc. in Q2 2016 and held it in 7 quarters.
Financial Architects (New Jersey)'s Intercept Pharmaceuticals, Inc. position peaked at $49K in Q3 2016.
147 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q1 2018.

Based on Financial Architects (New Jersey)'s 13F filing for Q1 2018, filed 23 Apr 2018.